Francesca Molinari

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Retrospective Consortium Analysis, Medicine, Pathology +5

Wild-Type <i>BRAF</i> Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Federica Di Nicolantonio, Miriam Martini, Francesca Molinari et al. · Journal of Clinical Oncology · 2008 · 1.6K citations · Full text

Kras Mutations, Gastrointestinal Oncology, Medicine +13

<i>PIK3CA</i> Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Andrea Sartore‐Bianchi, Miriam Martini, Francesca Molinari et al. · Cancer Research · 2009 · 735 citations

Side Kras, Pathology, Tumor Biology +17

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

Milo Frattini, Piercarlo Saletti, Elena Romagnani et al. · British Journal of Cancer · 2007 · 536 citations · Full text

<i>IDH1</i>mutations at residue p.R132 (IDH1^R132) occur frequently in high-grade gliomas but not in other solid tumors

Fonnet E. Bleeker, Simona Lamba, Sieger Leenstra et al. · Human Mutation · 2009 · 366 citations · Full text

Engineering, Genetics, Pathology +19